Free Subscription

  • Access 15 free news articles each month

Professional

Try one month for $7
  • Unlimited access to news,insights and opinions
  • Quarterly and weekly magazines
  • Independent research reports and forecasts
  • Quarterly webinars with industry experts
  • Q&A with retail leaders
  • Career advice
  • 10% discount on events
×

OTC cannabidiol set to open $200m market – but is there evidence to back it up?

A picture of a marijuana leaf lying on top of a cardboard box
The Australian Therapeutic Goods Administration’s (TGA) landmark interim decision to make registered low-dose cannabidiol (CBD) products available in pharmacies could open up a market worth more than $200 million, according to a Q3 report by medicinal cannabis experts Fresh Leaf Analytics.  The proposed new regulations mean that companies could apply for Schedule 3 (S3) or “over the counter” registration for oral or oromucosal CBD products such as oils, capsules, sprays and wafers, as ear